Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next
Shares of Structure Therapeutics Inc rose 5.6% to $66.75 in late-morning trade on Wednesday, recovering from early swings as investors sized up a newly disclosed patent license deal tied to Roche and Genentech’s oral obesity drug effort.